Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Phase II Multicenter, Not Comparative, Study of Multiple Doses of NEPA (netupitant + palonosetron) in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in Non-Hodgkin Lymphoma Patients Eligible for Autologous Hematopoietic Stem Cell Transplantation Receiving Multiple Days / High Dose Chemotherapy Regimens

Nicola Di Renzo, MD, Maurizio Musso, MD, Rosanna Scimè, MD, Giuseppe Milone, MD PhD, Tommasina Perrone, MD, Clara De Risi, MD, Domenico Pastore, MD PhD, Attilio Guarini, MD, Andrea Mengarelli, MD, Fabio Benedetti, MD, Patrizio Mazza, MD, Vera Capria, MD, Patrizia Chiusolo, Luca Cupelli, MD, Vincenzo Federico, MD, Valentina Bozzoli, PhD MD, Anna Rita Messa, Giorgina Specchia, MD

Blood (2019) 134 (Supplement_1): 1974.

https://doi.org/10.1182/blood-2019-125071

Published: 2019

Journal Articles

NEPA (netupitant + palonosetron) Administration Is Safe and Effective in cHL Patients Receiving ABVD Regimen: A Single-Center Real Life Experience

Vittorio Ruggero Zilioli, Periana Minga, Lara Crucitti, Erika Meli, Monica Luigia Torretta, Anna Esposito, Chiara Rusconi, Roberto Cairoli

Blood (2018) 132 (Supplement 1): 5374.

https://doi.org/10.1182/blood-2018-99-116543

Published: 2018

Journal Articles

Patient Reported Outcome (PRO) in Patients Receiving High and Moderate Emetogenic Chemotherapy (Ctx) - Results of a German Prospective Non-Interventional Study with Netupitant/Palonosetron Fixed Dose Combination (NEPA)

Meinolf Karthaus, P Klare, N Gazawi, MO Zahn, B Reimann, S Busch, Joerg Schilling

Blood (2018) 132 (Supplement 1): 4844.

https://doi.org/10.1182/blood-2018-99-113489

Published: 2018

Journal Articles

Quality of Life and Patient Reported Outcome (PRO) in Patients Receiving High and Moderate Emetogenic Chemotherapy (Ctx) - Results of a German Non-Interventional Study with NEPA - a Netupitant/Palonosetron Fixed Dose Combination

Meinolf Karthaus, MD, P Klare, V Heilmann, G Klausmann, Joerg Schilling

Blood (2017) 130 (Supplement 1): 2180.

https://doi.org/10.1182/blood.V130.Suppl_1.2180.2180

Published: 2017

Journal Articles

Chemotherapy-Induced Nausea and Vomiting (CINV) - First Results of a German Non-Interventional Study with NEPA - a Netupitant/Palonosetron Fixed Dose Combination

Meinolf Karthaus, P Klare, V Heilmann, G Klausmann, Joerg Schilling

Blood (2016) 128 (22): 3614.

https://doi.org/10.1182/blood.V128.22.3614.3614

Published: 2016

Journal Articles

A Randomized Trial of Olanzapine and Palonosetron versus Infused Ondansetron for the Treatment of Chemotherapy Induced Nausea and Vomiting in Patients Undergoing Hematopoietic Stem Cell Transplantation

Midori Nakagaki, BPharm, MSc, BCOP, Michael Barras, BPharm, GradDipClinPharm, PhD, Cameron Curley, MBBS, FRACP, FRCPA, Jason P Butler, MBBS, MMedSc, FRACP, FRCPA, Glen A Kennedy, MBBS, FRACP, FRCPA

Blood (2015) 126 (23): 1910.

https://doi.org/10.1182/blood.V126.23.1910.1910

Published: 2015

Journal Articles

Cardiac Safety of NEPA, a Fixed-Dose Antiemetic Combination, Administered Prior to Anthracycline-Based Chemotherapy

Meinolf Karthaus, MD, Matti Aapro, MD, Giada Rizzi, M.Sc., Marco Palmas, MD

Blood (2014) 124 (21): 4821.

https://doi.org/10.1182/blood.V124.21.4821.4821

Published: 2014

Journal Articles

No Evidence Of Increased Cyclophosphamide Toxicity Associated With The Antiemetic Agent NEPA, a Fixed-Dose Combination Of Netupitant and Palonosetron

Lee Schwartzberg, MD, FACP, Cristina Oprean, MD, Servando Cardona-Huerta, MD, Giada Rizzi, M.Sc., Giorgia Rossi, MD, Marco Palmas, MD, Meinolf Karthaus, MD, Matti Aapro, MD

Blood (2013) 122 (21): 2949.

https://doi.org/10.1182/blood.V122.21.2949.2949

Published: 2013

Journal Articles

Efficacy and Safety of Palonosetron in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients with Non-Hodgkin's Lymphomas Undergoing Repeated Cycles of Moderately Emetogenic Chemotherapy

Brian Choi, Gabriela Borsaru, Daniel Voisin, Gianluca Ballinari, Nicola Di Renzo

Blood (2011) 118 (21): 5196.

https://doi.org/10.1182/blood.V118.21.5196.5196

Published: 2011

Journal Articles

Impact of 5-Hydroxytryptamine- 3 Receptor Antagonist Step Therapy on Severe Chemotherapy-Induced Nausea and Vomiting Events in Patients with Lymphoma

Hind T Hatoum, PhD, Swu-Jane Lin, PhD, Sanjeev Balu, PhD, MBA

Blood (2011) 118 (21): 3137.

https://doi.org/10.1182/blood.V118.21.3137.3137

Published: 2011

Journal Articles

Combined Use of Multi-Day Doses of Palonosetron and Aprepitant with Low Dose Dexamethasone In Prevention of Nausea and Emesis Among Patients with Multiple Myeloma and Lymphoma Undergoing Autologous Hematopoietic Stem Cell Transplant (ASCT): A Pilot Study

Delva Deauna-Limayo, MD, Omar Aljitawi, MD, Siddhartha Ganguly, MD, Sunil Abhyankar, MD, Jo Wick, Joseph McGuirk, DO

Blood (2010) 116 (21): 1335.

https://doi.org/10.1182/blood.V116.21.1335.1335

Published: 2010

Journal Articles

Palonosetron Versus Other 5-HT 3 -Receptor Antagonists for the Prevention of Chemotherapy Induced Nausea and Vomiting In Patients with Hematologic Malignancies Treated In A Hospital Outpatient Setting

Chris Craver, MA, Julie Gayle, MPH, Sanjeev Balu, PhD, MBA, Deborah Buchner, PhD

Blood (2010) 116 (21): 2567.

https://doi.org/10.1182/blood.V116.21.2567.2567

Published: 2010

Journal Articles

Palonosetron Uniquely Inhibits Substance P-Mediated Neuronal Responses in Rat Nodose Ganglia.

Ying Li, M.D., Xiaoyin Wu, Ph.D., Camilo Rojas, Ph.D., Sergio Cantoreggi, Ph.D., Silvia Sebastiani, Ph.D., Barbara Slusher, Ph.D., M.B.A.

Blood (2009) 114 (22): 4826.

https://doi.org/10.1182/blood.V114.22.4826.4826

Published: 2009

Journal Articles

Palonosetron (PALO) Given Daily for up to 5 Days Is Significantly Better Than Ondansetron (ONDA) in the Prevention of Delayed CINV in Patients (pts) with Acute Myelogenous Leukemia (AML).

Gloria Mattiuzzi, MD, Jorge Cortes, MD, Deborah McCue, PhDP, B. Nebiyou Bekele, PhD, Lianchun Xiao, Gautam Borthakur, MD, Hagop Kantarjian, MD

Blood (2009) 114 (22): 993.

https://doi.org/10.1182/blood.V114.22.993.993

Published: 2009

Journal Articles

An Interim Analysis of Phase II, Open Randomized Comparative Trial: Alternate or Multiple-Day Dosing of Palonosetron (PALO) Is Effective and Safe in the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients (pts) with Leukemia Receiving High Dose Ara-C (HDAC).

Gloria Mattiuzzi, MD, Jorge Cortes, MD, Jennifer Cassat, Deborah Blamble, PHDP, B. Nebiyou Bekele, PhD, Miloslav Beran, MD, Gautam Borthakur, MD, Farhad Ravandi, MD, Jan Burger, MD, Hagop Kantarjian, MD

Blood (2007) 110 (11): 2840.

https://doi.org/10.1182/blood.V110.11.2840.2840

Published: 2007

Journal Articles

Long-Acting Serotonin Antagonist Palonosteron To Prevent Nausea and Vomiting after High-Dose Melphalan and Autograft in Myeloma.

S. Trifilio, K. Kaniecki, J. Zook, J. Pi, K. Carson, M. Fishman, K. Masino, N. Bainbridge, J. Mehta

Blood (2006) 108 (11): 5239.

https://doi.org/10.1182/blood.V108.11.5239.5239

Published: 2006

NARROW

NEPA (netupitant + palonosetron) Administration Is Safe and Effective in cHL Patients Receiving ABVD Regimen: A Single-Center Real Life Experience

Patient Reported Outcome (PRO) in Patients Receiving High and Moderate Emetogenic Chemotherapy (Ctx) - Results of a German Prospective Non-Interventional Study with Netupitant/Palonosetron Fixed Dose Combination (NEPA)

Quality of Life and Patient Reported Outcome (PRO) in Patients Receiving High and Moderate Emetogenic Chemotherapy (Ctx) - Results of a German Non-Interventional Study with NEPA - a Netupitant/Palonosetron Fixed Dose Combination

Chemotherapy-Induced Nausea and Vomiting (CINV) - First Results of a German Non-Interventional Study with NEPA - a Netupitant/Palonosetron Fixed Dose Combination

A Randomized Trial of Olanzapine and Palonosetron versus Infused Ondansetron for the Treatment of Chemotherapy Induced Nausea and Vomiting in Patients Undergoing Hematopoietic Stem Cell Transplantation

Cardiac Safety of NEPA, a Fixed-Dose Antiemetic Combination, Administered Prior to Anthracycline-Based Chemotherapy

No Evidence Of Increased Cyclophosphamide Toxicity Associated With The Antiemetic Agent NEPA, a Fixed-Dose Combination Of Netupitant and Palonosetron

Efficacy and Safety of Palonosetron in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients with Non-Hodgkin's Lymphomas Undergoing Repeated Cycles of Moderately Emetogenic Chemotherapy

Impact of 5-Hydroxytryptamine- 3 Receptor Antagonist Step Therapy on Severe Chemotherapy-Induced Nausea and Vomiting Events in Patients with Lymphoma

Combined Use of Multi-Day Doses of Palonosetron and Aprepitant with Low Dose Dexamethasone In Prevention of Nausea and Emesis Among Patients with Multiple Myeloma and Lymphoma Undergoing Autologous Hematopoietic Stem Cell Transplant (ASCT): A Pilot Study

Palonosetron Versus Other 5-HT 3 -Receptor Antagonists for the Prevention of Chemotherapy Induced Nausea and Vomiting In Patients with Hematologic Malignancies Treated In A Hospital Outpatient Setting

Palonosetron Uniquely Inhibits Substance P-Mediated Neuronal Responses in Rat Nodose Ganglia.

Palonosetron (PALO) Given Daily for up to 5 Days Is Significantly Better Than Ondansetron (ONDA) in the Prevention of Delayed CINV in Patients (pts) with Acute Myelogenous Leukemia (AML).

An Interim Analysis of Phase II, Open Randomized Comparative Trial: Alternate or Multiple-Day Dosing of Palonosetron (PALO) Is Effective and Safe in the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients (pts) with Leukemia Receiving High Dose Ara-C (HDAC).

Long-Acting Serotonin Antagonist Palonosteron To Prevent Nausea and Vomiting after High-Dose Melphalan and Autograft in Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only